Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-106 in Subjects Ages 18-75 With Generalized Myasthenia Gravis
Sponsor: COUR Pharmaceutical Development Company, Inc.
A PHASE1/PHASE2 clinical study on AChR Myasthenia Gravis and Generalized Myasthenia, this trial is actively recruiting participants. The trial is conducted by COUR Pharmaceutical Development Company, Inc. and has accumulated 10 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Mar 2025 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
▶ Show 5 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
Status: Recruiting → Not Yet Recruiting
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2024 — May 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Dec 2023 — Mar 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- COUR Pharmaceutical Development Company, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .